The Europe Herpes Simplex Virus Treatment Market should witness market growth of 2.8% CAGR during the forecast period (2022-2028).
The pipeline of vaccine candidates is anticipated to be released on the market throughout the forecast period. For example, GSK is working on the GSK4108771A vaccine, Sanofi Pasteur is developing the HSV529 vaccine, and RVx201 is a vaccine for HSV-2 that is a live attenuated vaccine. Moreover, EXD-12 is now undergoing preclinical testing. Moreover, efforts are being made by significant market participants to create and market vaccine candidates that are appropriate for herpes infection. For instance, research is being done to create highly effective, safe, and effective mRNA vaccine candidates. For instance, Moderna Inc. is working on mRNA-1608, a candidate for an mRNA vaccine.
Additionally, the efficiency and simplicity of administration of oral medication for herpes have significantly increased their demand. Oral versions of acyclovir, famciclovir, and valacyclovir are offered. Acyclovir, when taken orally, also lessens the average length of cold sore pain compared to a placebo, according to multiple research. In addition, acyclovir, administered orally, has a faster healing period than other therapy formulations. Moreover, oral formulations aid in delivering quick action, improving its appeal among the populace.
The prevalence of HSV-1 infection among young adults is lower in Northern European nations. European women are farmore likely than European men to be HSV-1 seropositive. Although there are significant variances in the proportion of people exposed to HSV-2, HSV-2 seropositivity is commonly found among Europeans over 12 years of age. Compared to other European nations, Bulgaria has a high HSV-2 seroprevalence. In every European nation, HSV-2 seropositivity rises with age and becomes more prevalent in the population, with some nations seeing a reduction in the older age groups. Therefore,the increasing prevalence of HSV infections and the research initiatives looking for better medications will drive the regional market's growth in the coming years.
The Germany market dominated the Europe Herpes Simplex Virus Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $140.9 Million by 2028. The UK market is anticipated to grow at a CAGR of 1.9% during (2022-2028). Additionally, The France market would exhibit a CAGR of 3.5% during (2022-2028).
Based on Drug Type, the market is segmented into Valacyclovir, Acyclovir, and Famciclovir. Based on Type, the market is segmented into Herpes simplex virus-1 Infection, and Herpes simplex virus-2 Infection. Based on Distribution Channel, the market is segmented into Drug Store & Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Pfizer, Inc., Amneal Pharmaceuticals, Inc., GlaxoSmithKline PLC, Teva Pharmaceuticals Industries Ltd., Glenmark Pharmaceuticals Limited, Fresenius SE & Co. KGaA, Novartis AG, Viatris, Inc., and Emcure Pharmaceuticals Limited.
The pipeline of vaccine candidates is anticipated to be released on the market throughout the forecast period. For example, GSK is working on the GSK4108771A vaccine, Sanofi Pasteur is developing the HSV529 vaccine, and RVx201 is a vaccine for HSV-2 that is a live attenuated vaccine. Moreover, EXD-12 is now undergoing preclinical testing. Moreover, efforts are being made by significant market participants to create and market vaccine candidates that are appropriate for herpes infection. For instance, research is being done to create highly effective, safe, and effective mRNA vaccine candidates. For instance, Moderna Inc. is working on mRNA-1608, a candidate for an mRNA vaccine.
Additionally, the efficiency and simplicity of administration of oral medication for herpes have significantly increased their demand. Oral versions of acyclovir, famciclovir, and valacyclovir are offered. Acyclovir, when taken orally, also lessens the average length of cold sore pain compared to a placebo, according to multiple research. In addition, acyclovir, administered orally, has a faster healing period than other therapy formulations. Moreover, oral formulations aid in delivering quick action, improving its appeal among the populace.
The prevalence of HSV-1 infection among young adults is lower in Northern European nations. European women are farmore likely than European men to be HSV-1 seropositive. Although there are significant variances in the proportion of people exposed to HSV-2, HSV-2 seropositivity is commonly found among Europeans over 12 years of age. Compared to other European nations, Bulgaria has a high HSV-2 seroprevalence. In every European nation, HSV-2 seropositivity rises with age and becomes more prevalent in the population, with some nations seeing a reduction in the older age groups. Therefore,the increasing prevalence of HSV infections and the research initiatives looking for better medications will drive the regional market's growth in the coming years.
The Germany market dominated the Europe Herpes Simplex Virus Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $140.9 Million by 2028. The UK market is anticipated to grow at a CAGR of 1.9% during (2022-2028). Additionally, The France market would exhibit a CAGR of 3.5% during (2022-2028).
Based on Drug Type, the market is segmented into Valacyclovir, Acyclovir, and Famciclovir. Based on Type, the market is segmented into Herpes simplex virus-1 Infection, and Herpes simplex virus-2 Infection. Based on Distribution Channel, the market is segmented into Drug Store & Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Pfizer, Inc., Amneal Pharmaceuticals, Inc., GlaxoSmithKline PLC, Teva Pharmaceuticals Industries Ltd., Glenmark Pharmaceuticals Limited, Fresenius SE & Co. KGaA, Novartis AG, Viatris, Inc., and Emcure Pharmaceuticals Limited.
Scope of the Study
By Drug Type
- Valacyclovir
- Acyclovir
- Famciclovir
By Type
- Herpes simplex virus-1 Infection
- Herpes simplex virus-2 Infection
By Distribution Channel
- Drug Store & Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Abbott Laboratories
- Pfizer, Inc.
- Amneal Pharmaceuticals, Inc.
- GlaxoSmithKline PLC
- Teva Pharmaceuticals Industries Ltd.
- Glenmark Pharmaceuticals Limited
- Fresenius SE & Co. KGaA
- Novartis AG
- Viatris, Inc.
- Emcure Pharmaceuticals Limited
Unique Offerings
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Europe Herpes Simplex Virus Treatment Market by Drug Type
Chapter 4. Europe Herpes Simplex Virus Treatment Market by Type
Chapter 5. Europe Herpes Simplex Virus Treatment Market by Distribution Channel
Chapter 6. Europe Herpes Simplex Virus Treatment Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- Abbott Laboratories
- Pfizer, Inc.
- Amneal Pharmaceuticals, Inc.
- GlaxoSmithKline PLC
- Teva Pharmaceuticals Industries Ltd.
- Glenmark Pharmaceuticals Limited
- Fresenius SE & Co. KGaA
- Novartis AG
- Viatris, Inc.
- Emcure Pharmaceuticals Limited
Methodology
LOADING...
Related Reports
Herpes Simplex Virus Treatment Market - Forecasts from 2024 to 2029
- Report
- 140 Pages
- Global
From
From
From
From
Herpes Simplex Virus Treatment Global Market Report 2024
- Report
- 200 Pages
- Global
From
About the Herpes Drug Market
The Herpes Drug market is a subset of the Infectious Diseases Drugs market, which includes drugs used to treat a variety of infectious diseases. Herpes drugs are used to treat the herpes simplex virus (HSV) and its associated conditions, such as genital herpes, cold sores, and shingles. These drugs can be administered orally, topically, or intravenously, depending on the severity of the infection. Commonly prescribed herpes drugs include acyclovir, valacyclovir, and famciclovir. Herpes drugs are Read more
This product is a market research report. Each license type allows a set number of users to access the report. Please select an option from the list below. This product is a market research report. This is a single user license, allowing one user access to the product. The product is a PDF. This product is a market research report. This is a site license, allowing all users within a given geographical location of your organization access to the product. The product is a PDF. This product is a market research report. This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF. 
